Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics Inc (VYGR) is a leader in developing gene therapies for central nervous system disorders through its proprietary TRACER™ platform. This page provides investors and researchers with essential updates on clinical developments, strategic partnerships, and scientific breakthroughs in AAV-based treatments.
Access curated press releases and news articles covering key milestones in Voyager’s pipeline, including therapies for Parkinson’s disease, ALS, and Friedreich’s ataxia. Stay informed about advancements in blood-brain barrier penetration technology and preclinical validation studies across multiple species.
Our repository features updates on clinical trial progress, regulatory developments, and collaborative research initiatives. Discover analysis of vector optimization achievements and manufacturing scalability efforts critical to gene therapy commercialization.
Bookmark this page for consolidated access to verified information about Voyager’s neurogenetic innovations. Check regularly for objective reporting on therapeutic candidate progression and industry leadership in CNS-targeted gene delivery solutions.
Voyager Therapeutics (NASDAQ: VYGR) announced on October 12, 2020, that its IND submission for VY-HTT01, aimed at treating Huntington's disease, is on clinical hold due to unresolved chemistry, manufacturing, and controls (CMC) issues. The FDA notified Voyager of this status, and the company expects specific feedback within 30 days. Huntington's disease affects over 40,000 individuals in the U.S. with no approved treatments targeting its underlying cause. Voyager is committed to addressing the CMC matters and advancing the clinical evaluation of VY-HTT01.
Voyager Therapeutics (NASDAQ: VYGR) announced a new employment agreement that includes inducement awards for a newly hired employee. The agreement includes a non-qualified stock option for 36,000 shares and restricted stock units for 6,000 shares, both effective on September 30 and October 1, 2020, respectively. The option has a ten-year term with an exercise price of $10.67, and it vests over four years. The restricted stock units vest over three years. These awards aim to attract talent to support the company’s focus on developing gene therapies for severe neurological diseases.
Voyager Therapeutics (NASDAQ: VYGR) has appointed Nancy Vitale as an independent director to its Board of Directors, effective September 15, 2020. Vitale has over 25 years of human resources experience, including a role as Chief Human Resource Officer at Genentech. Her expertise is expected to enhance Voyager's focus on patient-centric culture and employee wellbeing. Vitale also co-founded a human resources consulting firm and will serve on the Board's Compensation Committee. This appointment aims to bolster the company's mission to develop treatments for severe neurological diseases.
Voyager Therapeutics (NASDAQ: VYGR) announced the appointment of Michelle Quinn Smith as Chief Human Resources Officer, bringing over 30 years of HR experience. Previously at Flagship Pioneering and Takeda Pharmaceuticals, Smith aims to enhance organizational strategies. Voyager approved inducement grants for her, including 100,500 stock options and 17,000 restricted stock units. The options have a ten-year term with an exercise price of $10.40 per share, and vest over four years. Voyager focuses on gene therapies for severe neurological diseases.
NBIb-1817 (VY-AADC), an investigational gene therapy for Parkinson's disease, demonstrated sustained improvements in motor function over three years. Data from the Phase Ib PD-1101 trial revealed that 14 of 15 patients reported enhanced disease staging, with reduced "Off" time by up to 1.91 hours and increased "On" time without dyskinesia by up to 2.23 hours. Additionally, medication requirements were lowered significantly, with reductions in daily dosages. The company plans to re-initiate enrollment in the registrational RESTORE-1 clinical trial later this year.
Voyager Therapeutics (NASDAQ: VYGR) has announced significant updates on their investigational gene therapy, VY-AADC, for advanced Parkinson's disease, with presentations at the International Parkinson and Movement Disorder Virtual Congress from September 12-16, 2020. Key findings include three-year safety and clinical outcomes from the PD-1101 trial and 24-month results from the PD-1102 trial. Moreover, Voyager will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 9, 2020. More details can be found on their website.
Voyager Therapeutics (NASDAQ: VYGR) will release its Q2 2020 financial results and corporate updates on August 10, 2020, before U.S. markets open. The company is focused on gene therapy for severe neurological diseases and will participate in three virtual investor conferences from August 10 to August 12. These events highlight Voyager's commitment to advancing AAV gene therapy and its pipeline targeting therapies for diseases like Parkinson's and Huntington's.
Voyager Therapeutics (NASDAQ: VYGR) announced an employment agreement with a new hire that includes inducement awards of stock options and restricted stock units. The stock option grant of 36,000 shares has an exercise price of $12.82 per share, matching the closing price on the grant date of June 15, 2020. The option vests over four years, while the restricted stock units for 6,000 shares vest annually over three years starting July 1, 2020. These awards were approved by the Compensation Committee in compliance with Nasdaq rules, reflecting the company's commitment to attracting talent.
Voyager Therapeutics reported its Q1 2020 financial results, ending with over $250M in cash, projected to fund operations until mid-2022. The company highlighted 14 presentations at the upcoming ASGCT meeting, addressing several therapies for neurological diseases including Huntington’s and ALS. Voyager established a new Scientific Advisory Board with industry experts to enhance its research efforts. Collaboration revenues increased to $18.1M, up from $5.2M in Q1 2019, while R&D expenses rose to $32.3M due to ongoing clinical trials.